First, this is the first study to evaluate the predictive value of plasmatic levels of HSP90α at diagnosis in advanced lung cancer patients treated with PD-1/PD-L1 inhibitors plus chemotherapy. Here, HSP90AA1 is linked to lung carcinoma.